What did Cantor Fitzgerald do on March 12, 2026 for CDXS?

Cantor Fitzgerald reiterated an **Overweight** rating on March 12, 2026 for Codexis. The note followed Codexis’s Q4 results and included no new price target. This action kept the existing positive stance on CDXS.

How should investors interpret the CDXS analyst rating?

A maintained **Overweight** rating indicates the analyst expects CDXS to outperform peers. It is a supportive signal, not a new endorsement. Investors should wait for concrete commercial milestones before changing allocations.

Did the analyst change the CDXS price target?

No. Cantor Fitzgerald did not publish a new **CDXS price target** with the March 12, 2026 note. The maintained rating kept prior valuation assumptions in place.

What is Meyka’s view on CDXS after the rating action?

Meyka AI rates CDXS with a grade of **B**, reflecting benchmark and sector comparisons, growth, and analyst consensus. We view the maintained rating as constructive but note that signed CDMO deals are key future catalysts.

Analyst Ratings

Cantor Fitzgerald Maintains Overweight on Codexis (CDXS) March 2026

ByHuzaifa Zahoor March 13, 2026March 13, 2026

Cantor Fitzgerald maintained its Overweight rating on Codexis, Inc. (CDXS) on March 12, 2026 following the Q4 results. The CDXS analyst rating stayed positive, with the firm citing the company’s commercial updates and execution progress. We view this as a reaffirmation rather than a directional change. The note did not include a new price target. Cantor’s call keeps investor focus on revenue cadence and commercial milestones tied to enzyme and CDMO work.